China News Agency, Guangzhou, December 5th (Reporter Wang Jian) According to the news from the Nansha District Market Supervision Bureau of Guangzhou City on the 5th, the district has continued to create a "fusion agent" for industrial development in recent years, focusing on building a new model of Hong Kong and Macao pharmaceutical equipment production and sales, and actively promoting the " Carry out the reform of the drug marketing authorization holder system in the Guangdong-Hong Kong-Macao Greater Bay Area, and open up a "green channel" for Hong Kong and Macao enterprises that meet relevant conditions to develop in Nansha.
According to the Nansha District Market Supervision Bureau, in order to build a biopharmaceutical industry cluster, give full play to the main role of enterprise innovation, and promote the transformation of research and development results in Nansha, the bureau actively tried to guide biopharmaceutical companies to intervene in advance, establish a "green channel", and explore the establishment of a jurisdiction Drug and medical device review and inspection service agencies provide full-chain services for enterprise license declaration, registration and filing consultation and other projects.
The relevant person in charge of the Nansha District Market Supervision Bureau stated that the bureau is taking multiple measures to promote the "reform of the drug marketing authorization holder system in the Guangdong-Hong Kong-Macao Greater Bay Area" and actively strengthen docking with Hong Kong and Macao enterprises.
According to the person in charge, the Bureau has facilitated the Zingo? Jinlaiyi, a needle-free transdermal injection drug delivery system for lidocaine hydrochloride powder of Hong Kong Lepu Pharmaceutical Company, to be commissioned by Nansha Zhaoke Pharmaceutical (Guangzhou) Co., Ltd.; to support the development of Hong Kong and Macao OTC (over-the-counter) drug cross-border e-commerce import pilot, relying on chain stores, promote the promotion of Class B OTC drug counters in Nansha; and carry out strategic cooperation with China Resources Guangdong Pharmaceutical Co., Ltd. A new mode of drug storage and distribution in medical institutions.
In addition, in order to solve the key problems of enterprise drug research and development, Nansha District also actively promotes the pilot project of the "white list" system for the import of drug research and development materials, and combines the "Several Measures of the General Administration of Customs to Support Guangzhou Nansha to Deepen Guangdong-Hong Kong-Macao Comprehensive Cooperation Facing the World", through multiple channels Solicit the needs of enterprises, strengthen research with customs and other departments, and continue to explore and improve the import facilitation measures for biomedical research and development.
(Finish)